About Drugabilis

About Drugabilis

Drugabilis is a fully independent, privately owned, drugability-focused drug discovery and preclinical-development company located in the southwest of Paris, France. It is the first CRO specialized in pharmaceutical physicochemical characterization and formulation as applied to the early selection of new drug candidates. It delivers both experimental support and consulting services to its customer’s research efforts by supporting the selection of drugable compounds and delivery systems.

It was founded on October 7th, 2004, after the Pfizer relocation of the Discovery Research Operations previously based at the former Jouveinal/Parke Davis Fresnes site. Its management and scientists have extensive experience in the support of therapeutic research programs.

Joel Vacus started Drugabilis to help research organisations select higher-quality and more robust drug candidates, simplifying preclinical development phases and securing faster return on research investments.

After 13 years working for major pharmaceutical companies at the Discovery-Development interface, he strongly believes research projects need to be closely supported by specialised scientists, able to characterise the physicochemical properties of research compounds, to quickly and rationally formulate them for animal experiments and to correctly predict if and how Discovery findings will apply to drug product prototypes in development.

People

People

 

 Over 130 years of experience in Pharmaceutical Research and Development

 Experience gained in a wide range of international companies

 













Joel Vacus
Ph.D. • CEO and CSO
    
Prior to setting up Drugabilis in 2004, Dr. Joel Vacus held various positions at Rhône-Poulenc Rorer, Parke-Davis and Pfizer during the first 12 years of his career. His roles within Pfizer included Head of Pharmaceutical Sciences, Member of the Research Leadership Team and Member of the Site Leadership Team at the Fresnes site (France), where he had earlier been appointed as Scientific Advisor to the Pharmaceutical Sciences Department.

For five years, Dr. Joel Vacus built and led “Pharm Sci Discovery Support” at Parke-Davis Fresnes, and later on at Pfizer, aiming to improve new drug candidate selection through earlier assessment of research compounds’ drug-like properties. He had previously worked for five years in preclinical development at Rhône-Poulenc Rorer where he and his team dealt more specifically with early formulations used for animal testing and with physico-chemical characterisation of new chemical entities.

Since then, Dr. Joel Vacus has also acquired strong experience in new drug delivery systems, including micellar systems, liposomes, nanoparticles, self-emulsifying systems and non-viral vectors for gene therapy. He is the author of several patents and publications in these fields. He has a chemistry and physico-chemistry background (graduated from ESPCI - Paris) and has a Ph.D. in inorganic chemistry.

Joel Vacus coordinates most of the trouble-shooting studies and a large number of client projects outsourced to Drugabilis. He also works as strategic and scientific consultant to some of Drugabilis’ regular customers.







 


 

Drugability

Drugability

Modern drug candidates are expected to show strong physicochemical and biopharmaceutical profiles as well as consistent delivery options before accessing preclinical development.

In order to improve candidate quality, research programs are ever more reliant upon early physicochemical properties monitoring and rational formulation design for in vivo experiments.

Over the last decade, the need for new methodologies to earlier identify more drugable molecules has clearly emerged in the pharmaceutical industry as a key element to secure return-on-investment in discovery and accelerate research-to-development transition.

Drugabilis is the first CRO specialised in pharmaceutical drugability for research. We deliver both experimental support and consulting services to our customer’s research efforts, by promoting the emergence and selection of highly-drugable compounds and suitable delivery systems, from idea to preclinical candidate.

Technical platform

Technical platform

The technologies we use and the methodologies we develop are specifically adapted for Discovery support. Whenever possible, we design and set-up micro-methods, minimising the drug substance quantities required for characterisation of research compounds or early formulation studies.

Thanks to a very comprehensive technical platform and to its strong characterisation capabilities and thanks to an original expertise in early formulation design, Drugabilis delivers high added-value support at all stages of the Discovery process.

We allow Discovery teams to secure their candidate selection process and to smoothen the transition of their projects to development, maximising the "return-on-research-investments" chances...

 

 



View gallery >



HPLC-UV-ELSD
Sample prep robots
TGA & TGA-FTIR
DSC
Optical microscopy
Hot-stage microscopy
Raman microscopy
Water sorption & hygroscopicity
Powder X-ray diffraction
Light scattering granulometry
Viscosimeter

Repeat customers

Repeat customers